Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina

Journal of Infectious Diseases

Volumn 180, Issue 1, 1999, Pages 99-105

  Fiscus, Susan A ^a,h   Adimora, Adaora A ^a,b   Schoenbach, Victor J ^b   McKinney, Ross ^c   Lim, Wilma ^a   Rupar, David ^d   Kenny, Jean ^e   Woods, Charles ^f   Wilfert, Catherine ^c   Johnson, Victoria A ^g  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

^e EAST CAROLINA UNIVERSITY   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ADULT; ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PATIENT COUNSELING; PERINATAL INFECTION; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CLINICAL TRIALS; COUNSELING; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; NORTH CAROLINA; PATIENT COMPLIANCE; PREGNANCY; ZIDOVUDINE;

EID: 0033044224     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314840     Document Type: Article

References (30)

1. Connor EM, Sperling RS, Gelbert R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331:1173-80.
2. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Engl J Med 1996;335:1621-9.
3. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmue globulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease. Results of pediatric AIDS clinical trials group protocol 185. J Infect Dis. 1999;179:567-75.
4. Centers for Disease Control and Prevention. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission. Thailand, 1996-1998. MMWR Morb Mortal Wkly Rep 1998;47:151-4.
5. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy in transmission in rural and urban counties. JAMA 1996;275:1483-8.
6. Boyer PJ, Dillon M, Navaie M, et al. Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or delivery. JAMA 1994;271:1925-930.
7. Matheson PB, Abrams EJ, Thomas PA, et al. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 1995;172:353-8.
8. Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy and the subsequent reduction on the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J Infect Dis 1996;174:1207-11.
9. Kuhn L, Abrams EJ, Matheson PB, et al. Timing of maternal-infant HIV transmission associations between intrapartum factors and early polymerase chain reaction results. AIDS 1997;11:429-35.
10. Frenkel LM, Cowles MK, Shapiro DE, et al. Analysis of the maternal components of the AIDS Clinical Trial Group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997;175:971-4.
11. Steketee RW, Simonds RJ, Nesheim S, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS 1998;12:301-8.
12. Simpson BJ, Shapiro ED, Andiman WA. Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:145-52.
13. Division of AIDS, National Institute of Allergy and Infectious Diseases. DAIDS Virology Manual for HIV Laboratories. Washington, DC: US Department of Health and Human Services, 1997: publication no. NIH-97-3828.
14. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS 1995;9:F7-FH.
15. Japour, AJ, Mayers DL, Johnson VA, et al. A standardized peripheral mononuclear cell culture assay for the determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993;32:1095-101.
16. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753-9.
17. Bryson, YJ, Luzuriaga K, Sullivan JL, Wara DW. Proposed definitions for in utero versus intrapartum transmission of HIV-1. N Engl J Med 1992;327:1246-7.
18. Gwinn M, Papparoanou M, George JR, et al. Prevalence of HIV infection in childbearing women in the United States: surveillance using newborn blood samples. JAMA 1991;265:1704-8.
19. Centers for Disease Control and Prevention. USPHS Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep 1998;47(RR-2):1-30.
20. Wiznia AA, Crane M, Lambert G, Sansary J, Harris A, Solomom L. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center. JAMA 1996;275:1504-6.
21. Centers for Disease Control and Prevention. Success in implementing Public Health Service guidelines to reduce perinatal transmission of HIV Loiusiana, Michigan, New Jersey, and South Carolina, 1993, 1995, and 1996. MMWR Morb Mortal Wkly Rep 1998;47:688-94.
22. Walter EB, Lampe MA, Livingston E, Royce RA. How do North Carolina prenatal care providers counsel and test pregnant women for HIV? N C Med J 1998;59:105-9.
23. Melvin AJ, Burchett SK, Watts DH, et al. Effect of pregnancy and zidovudine therapy in viral load in HIV-1 infected women. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:232-6.
24. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of HIV. N Engl J Med 1998;339:1409-14.
25. Cu-Uvin S, Caliendo A, Russo R, et al. HIV-1 RNA levels in the genital tract of women on antiretroviral therapy (abstract 713). In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago, 4 February 1998). Alexandria, VA: Infectious Diseases Society of America, 1998.
26. Palmore MP, Ellerbrock T, Lennox JL, et al. Does antiretroviral therapy reduce the amount of HIV in vaginal secretions of HIV-infected women? [abstract III 3]. Source: National Conference of Women and HIV (Pasadena, CA, 4-7 May 1997). 1997:113 (http://130.14.32.43/cgi-bin/VERSION_A/IGM-client?15125+detail+2).
27. Blanche S, Mayeaux MJ, Mandelbrot L, Rouzioux C, Delfraissey JF. Acceptability and impact of zidovudine prevention on mother to child HIV-1 transmission in France [abstract 380]. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC, January 1997). Alexandria, VA: Infectious Disease Society of America, 1997.
28. Subbarao S, Wright T, Elerbrock T, Lennox JL, Hart C. Genotypic evidence of local HIV expression in the female genital tract (abstract 708). In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago, 4 February 1998). Alexandria, VA: Infectious Disease Society of America, 1998.
29. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557-64.
30. Colgrove R, Pitt J, Chang PH, Welles SL, Japour AJ. Selective vertical transmission of HIV-1 antirectroviral resistance mutations. AIDS 1998;12:2281-8.